A. M. Amin, S. E. Soliman and H. A. El-Aziz
This paper addresses the development of a new radiopharmaceutical for cancer imaging and therapy. The optimization of the labeling conditions of thymidine analogue, melphalan, with 125I is described. High radiochemical yield 96.8 % was obtained by reacting 0.2 mg melphalan with 125I in the presence of choloramin-T as oxidizing agent in 0.5M phosphate buffer, pH 7, at 70°C for 15 minutes. Preliminary in-vivo study was done in non-tumor bearing mice. The results revealed that this new tracer, 125I-melphalan, has a high affinity to be localized in the tumor site for a long period which indicates the specificity of this tracer to the tumor cells. Copyright © 2009 John Wiley & Sons, Ltd.